Loading...
•
Dec 31, 2021
Zimmer Biomet Q4 2021 Earnings Report
Zimmer Biomet's financial performance in Q4 2021 was impacted by the COVID-19 pandemic and China's volume-based procurement.
Key Takeaways
Zimmer Biomet reported a decrease in net sales for the fourth quarter of 2021, alongside a net loss, although adjusted earnings per share showed a positive figure. The company's performance was impacted by the ongoing COVID-19 pandemic and China's volume-based procurement.
Fourth quarter net sales decreased by 2.3% to $2.038 billion, a 0.8% decrease on a constant currency basis.
Diluted loss per share for the fourth quarter was $0.40, while adjusted diluted earnings per share were $1.95.
Net loss for the fourth quarter was $84.0 million, but adjusted net earnings were $409.2 million.
The company provided full-year 2022 financial guidance for RemainCo Zimmer Biomet.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is providing the following full-year 2022 financial guidance for RemainCo Zimmer Biomet – this guidance does not include any projected financial results from the businesses that are part of the planned spinoff of ZimVie from the Company.
Revenue & Expenses
Visualization of income flow from segment revenue to net income